MedPath

Dapansutrile

Generic Name
Dapansutrile
Drug Type
Small Molecule
Chemical Formula
C4H7NO2S
CAS Number
54863-37-5
Unique Ingredient Identifier
2Z03364G96
Background

Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

Clinical Trials
Related News

Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

Phase 2
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebo
First Posted Date
2023-09-21
Last Posted Date
2024-08-14
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
300
Registration Number
NCT06047262
Locations
🇨🇭

University Hospital Basel, Basel, Switzerland

Advanced Cardiovascular Imaging of the Systemic Effects of Inflammasome Activation

Early Phase 1
Not yet recruiting
Conditions
Myocardial Infarction
Interventions
Other: Placebo
First Posted Date
2023-05-30
Last Posted Date
2023-10-02
Lead Sponsor
University of Virginia
Target Recruit Count
60
Registration Number
NCT05880355
Locations
🇺🇸

University of Virginia, Charlottesville, Virginia, United States

Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Phase 2
Recruiting
Conditions
Gout
Gout Flare
Arthritis
Gout Attack
Acute Gout Flare
Joint Pain
Gouty Arthritis
Interventions
Other: Placebo Tablet
First Posted Date
2022-12-20
Last Posted Date
2024-12-04
Lead Sponsor
Olatec Therapeutics LLC
Target Recruit Count
300
Registration Number
NCT05658575
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona, United States

🇺🇸

Arizona Arthritis & Rheumatology Associates (AARA), P.C. - Mesa, Mesa, Arizona, United States

and more 30 locations

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Phase 1
Recruiting
Conditions
Melanoma
Interventions
First Posted Date
2021-07-21
Last Posted Date
2024-05-30
Lead Sponsor
April Salama, M.D.
Target Recruit Count
26
Registration Number
NCT04971499
Locations
🇺🇸

Duke Cancer Center, Durham, North Carolina, United States

Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome

Phase 2
Terminated
Conditions
Cytokine Release Syndrome
Covid19
Interventions
Drug: placebo capsules
First Posted Date
2020-09-07
Last Posted Date
2023-04-13
Lead Sponsor
Olatec Therapeutics LLC
Target Recruit Count
49
Registration Number
NCT04540120
Locations
🇺🇸

Las Vegas Medical Research, LLC, Las Vegas, Nevada, United States

🇺🇸

Invesclinic U.S. LLC, Fort Lauderdale, Florida, United States

🇺🇸

C&R Research Services USA, Houston, Texas, United States

and more 6 locations

Pilot Study of Dapansutrile Capsules in Schnitzler's Syndrome

Phase 2
Terminated
Conditions
Schnitzler Syndrome
Interventions
First Posted Date
2018-07-23
Last Posted Date
2024-02-02
Lead Sponsor
Olatec Therapeutics LLC
Target Recruit Count
2
Registration Number
NCT03595371
Locations
🇳🇱

Radboudumc, Nijmegen, Netherlands

Study of Dapansutrile Capsules in Heart Failure

Phase 1
Completed
Conditions
Systolic Heart Failure
Interventions
Drug: Placebo capsules
First Posted Date
2018-05-23
Last Posted Date
2020-01-09
Lead Sponsor
Olatec Therapeutics LLC
Target Recruit Count
30
Registration Number
NCT03534297
Locations
🇺🇸

Virginia Commonwealth University - Pauley Heart Center, Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy